Life Sciences and Healthcare Services

Faced with rising product development costs and stagnant organic expansion, many life sciences companies see mergers & acquisitions (M&As) as the key to future growth. Yet numerous studies in recent years reveal that between 50-80 percent of M&As fail to produce their anticipated benefits. Why? In most cases experts agree that poor post-merger integration, and especially talent management, is largely to blame.

The withdrawal of several high-profile pharmaceuticals from the market and some well-publicized problems with a number of medical devices have greatly magnified public concerns about the safety and efficacy of therapeutic products. The new administration in Washington is pushing for government-funded comparative effectiveness studies. CMS and private payors are more reluctant than ever to offer reimbursement for “me-too” products. Non-inferiority isn’t good enough anymore. In this demanding environment with the well-being of patients and hundreds of millions of dollars at stake, developing outstanding regulatory leaders has never been more important – or more difficult.